Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

Pourquoi ce travail est-il dans la base ?

Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.

Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Écart entre enseignants

0,348 · la distance entre les deux têtes enseignantes sur ce seul travail

Statut de validation

score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Résumé

PURPOSE: The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in previously treated advanced gastric cancer. PATIENTS AND METHODS: Patients with advanced gastric cancer that progressed after one or two lines of systemic chemotherapy were randomly assigned to everolimus 10 mg/d (assignment schedule: 2:1) or matching placebo, both given with BSC. Randomization was stratified by previous chemotherapy lines (one v two) and region (Asia v rest of the world [ROW]). Treatment continued until disease progression or intolerable toxicity. Primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), overall response rate, and safety. RESULTS: Six hundred fifty-six patients (median age, 62.0 years; 73.6% male) were enrolled. Median OS was 5.4 months with everolimus and 4.3 months with placebo (hazard ratio, 0.90; 95% CI, 0.75 to 1.08; P = .124). Median PFS was 1.7 months and 1.4 months in the everolimus and placebo arms, respectively (hazard ratio, 0.66; 95% CI, 0.56 to 0.78). Common grade 3/4 adverse events included anemia, decreased appetite, and fatigue. The safety profile was similar in patients enrolled in Asia versus ROW. CONCLUSION: Compared with BSC, everolimus did not significantly improve overall survival for advanced gastric cancer that progressed after one or two lines of previous systemic chemotherapy. The safety profile observed for everolimus was consistent with that observed for everolimus in other cancers.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

La notice

Revue

Journal of Clinical Oncology

Thématique

Gastric Cancer Management and Outcomes

Domaine

Medicine

Établissements canadiens

—

Organismes subventionnaires

West China Hospital, Sichuan UniversityBC Cancer AgencyNovartis PharmaChugai PharmaceuticalRuijin HospitalHebei Medical UniversityNanfang HospitalInstitut Gustave-RoussySchool of Medicine, Shanghai Jiao Tong UniversityPeking UniversityKU LeuvenSichuan UniversityUniversitair Ziekenhuis GentSun Yat-sen UniversityChina Medical UniversityFudan UniversityMcGill UniversitySir Run Run Shaw HospitalShanghai Jiao Tong UniversityHarbin Medical UniversitySanofiSoochow UniversityGlaxoSmithKline

Mots-clés

EverolimusMedicineRamucirumabInternal medicineHazard ratioClinical endpointAdverse effectCancerPlaceboPhases of clinical researchGastroenterologyChemotherapySurgeryOncologyClinical trialConfidence intervalPathology

Résumé présent dans OpenAlex

oui

API

/api/v1/works/W2134392974